Serologic profile of myasthenia gravis and distinction from the Lambert- Eaton myasthenic syndrome

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Autoimmune serologic testing is indicated in the initial investigation of a patient believed to have myasthenia gravis (MG) or the Lambert-Eaton myasthenic syndrome (LES). Serologic confirmation of mild, ocular, or recent- onset MG is ensured by a panel of antibody tests more than by any single test, and by testing before commencing immunosuppressant therapy. A positive result for the acetylcholine receptor (AChR)-binding antibody test is characteristic but not diagnostic of MG. AChR-binding or striational autoantibodies are found in 13% of patients with LES, a disorder that tends to be mistaken for MG when the presenting symptoms include ocular or bulbar muscle weakness. Seropositivity for P/Q-type calcium channel-binding antibodies distinguishes these disorders (LES 95%; MG ≤5%). The AChR- blocking antibody assay is not recommended as a screening test for MG, but if the assay for AChR-modulating antibodies is positive, a positive result for AChR-blocking antibodies provides an additional quantitative baseline for future comparisons in monitoring an individual patient's immune response in relation to the clinical course and treatment. Seropositivity for striational antibodies is most predictive of thymoma when coupled with an AChR modulating antibody value of >90% AChR loss. Results of all serologic tests must be interpreted by a physician in the context of a patient's history, physical and electromyographic findings, response to Tensilon, chest imaging, and other serological findings (e.g., striational antibodies, thyroid and gastric autoantibodies, and P/Q-type calcium channel-binding antibodies).

Original languageEnglish (US)
JournalNeurology
Volume48
Issue number4 SUPPL. 5
StatePublished - Apr 1997

Fingerprint

Lambert-Eaton Myasthenic Syndrome
Myasthenia Gravis
Cholinergic Receptors
Antibodies
Q-Type Calcium Channels
P-Type Calcium Channels
Blocking Antibodies
Autoantibodies
Edrophonium
Thymoma
Muscle Weakness
Physiologic Monitoring
Serologic Tests
Immunosuppressive Agents
Stomach
Thyroid Gland
Thorax
Physicians

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Serologic profile of myasthenia gravis and distinction from the Lambert- Eaton myasthenic syndrome. / Lennon, Vanda A.

In: Neurology, Vol. 48, No. 4 SUPPL. 5, 04.1997.

Research output: Contribution to journalArticle

@article{ac6c6b67df7a4201b88db903556f0f11,
title = "Serologic profile of myasthenia gravis and distinction from the Lambert- Eaton myasthenic syndrome",
abstract = "Autoimmune serologic testing is indicated in the initial investigation of a patient believed to have myasthenia gravis (MG) or the Lambert-Eaton myasthenic syndrome (LES). Serologic confirmation of mild, ocular, or recent- onset MG is ensured by a panel of antibody tests more than by any single test, and by testing before commencing immunosuppressant therapy. A positive result for the acetylcholine receptor (AChR)-binding antibody test is characteristic but not diagnostic of MG. AChR-binding or striational autoantibodies are found in 13{\%} of patients with LES, a disorder that tends to be mistaken for MG when the presenting symptoms include ocular or bulbar muscle weakness. Seropositivity for P/Q-type calcium channel-binding antibodies distinguishes these disorders (LES 95{\%}; MG ≤5{\%}). The AChR- blocking antibody assay is not recommended as a screening test for MG, but if the assay for AChR-modulating antibodies is positive, a positive result for AChR-blocking antibodies provides an additional quantitative baseline for future comparisons in monitoring an individual patient's immune response in relation to the clinical course and treatment. Seropositivity for striational antibodies is most predictive of thymoma when coupled with an AChR modulating antibody value of >90{\%} AChR loss. Results of all serologic tests must be interpreted by a physician in the context of a patient's history, physical and electromyographic findings, response to Tensilon, chest imaging, and other serological findings (e.g., striational antibodies, thyroid and gastric autoantibodies, and P/Q-type calcium channel-binding antibodies).",
author = "Lennon, {Vanda A}",
year = "1997",
month = "4",
language = "English (US)",
volume = "48",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4 SUPPL. 5",

}

TY - JOUR

T1 - Serologic profile of myasthenia gravis and distinction from the Lambert- Eaton myasthenic syndrome

AU - Lennon, Vanda A

PY - 1997/4

Y1 - 1997/4

N2 - Autoimmune serologic testing is indicated in the initial investigation of a patient believed to have myasthenia gravis (MG) or the Lambert-Eaton myasthenic syndrome (LES). Serologic confirmation of mild, ocular, or recent- onset MG is ensured by a panel of antibody tests more than by any single test, and by testing before commencing immunosuppressant therapy. A positive result for the acetylcholine receptor (AChR)-binding antibody test is characteristic but not diagnostic of MG. AChR-binding or striational autoantibodies are found in 13% of patients with LES, a disorder that tends to be mistaken for MG when the presenting symptoms include ocular or bulbar muscle weakness. Seropositivity for P/Q-type calcium channel-binding antibodies distinguishes these disorders (LES 95%; MG ≤5%). The AChR- blocking antibody assay is not recommended as a screening test for MG, but if the assay for AChR-modulating antibodies is positive, a positive result for AChR-blocking antibodies provides an additional quantitative baseline for future comparisons in monitoring an individual patient's immune response in relation to the clinical course and treatment. Seropositivity for striational antibodies is most predictive of thymoma when coupled with an AChR modulating antibody value of >90% AChR loss. Results of all serologic tests must be interpreted by a physician in the context of a patient's history, physical and electromyographic findings, response to Tensilon, chest imaging, and other serological findings (e.g., striational antibodies, thyroid and gastric autoantibodies, and P/Q-type calcium channel-binding antibodies).

AB - Autoimmune serologic testing is indicated in the initial investigation of a patient believed to have myasthenia gravis (MG) or the Lambert-Eaton myasthenic syndrome (LES). Serologic confirmation of mild, ocular, or recent- onset MG is ensured by a panel of antibody tests more than by any single test, and by testing before commencing immunosuppressant therapy. A positive result for the acetylcholine receptor (AChR)-binding antibody test is characteristic but not diagnostic of MG. AChR-binding or striational autoantibodies are found in 13% of patients with LES, a disorder that tends to be mistaken for MG when the presenting symptoms include ocular or bulbar muscle weakness. Seropositivity for P/Q-type calcium channel-binding antibodies distinguishes these disorders (LES 95%; MG ≤5%). The AChR- blocking antibody assay is not recommended as a screening test for MG, but if the assay for AChR-modulating antibodies is positive, a positive result for AChR-blocking antibodies provides an additional quantitative baseline for future comparisons in monitoring an individual patient's immune response in relation to the clinical course and treatment. Seropositivity for striational antibodies is most predictive of thymoma when coupled with an AChR modulating antibody value of >90% AChR loss. Results of all serologic tests must be interpreted by a physician in the context of a patient's history, physical and electromyographic findings, response to Tensilon, chest imaging, and other serological findings (e.g., striational antibodies, thyroid and gastric autoantibodies, and P/Q-type calcium channel-binding antibodies).

UR - http://www.scopus.com/inward/record.url?scp=0030907731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030907731&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030907731

VL - 48

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4 SUPPL. 5

ER -